JP2016520082A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016520082A5 JP2016520082A5 JP2016514047A JP2016514047A JP2016520082A5 JP 2016520082 A5 JP2016520082 A5 JP 2016520082A5 JP 2016514047 A JP2016514047 A JP 2016514047A JP 2016514047 A JP2016514047 A JP 2016514047A JP 2016520082 A5 JP2016520082 A5 JP 2016520082A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- seq
- medicament
- medicament according
- heavy chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 206010028980 Neoplasm Diseases 0.000 claims description 11
- 206010033128 Ovarian cancer Diseases 0.000 claims description 11
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 9
- 102100035139 Folate receptor alpha Human genes 0.000 claims description 8
- 101001023230 Homo sapiens Folate receptor alpha Proteins 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 8
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 238000003364 immunohistochemistry Methods 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 4
- 208000020816 lung neoplasm Diseases 0.000 claims description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 4
- 229920001184 polypeptide Polymers 0.000 claims description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 4
- 150000003431 steroids Chemical class 0.000 claims description 4
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010014733 Endometrial cancer Diseases 0.000 claims description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 2
- 229960003957 dexamethasone Drugs 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 229910052697 platinum Inorganic materials 0.000 claims description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 2
- 206010046766 uterine cancer Diseases 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 18
- 125000003275 alpha amino acid group Chemical group 0.000 claims 7
- 239000000427 antigen Substances 0.000 claims 5
- 102000036639 antigens Human genes 0.000 claims 5
- 108091007433 antigens Proteins 0.000 claims 5
- 239000012634 fragment Substances 0.000 claims 5
- 239000013612 plasmid Substances 0.000 claims 4
- 201000002628 peritoneum cancer Diseases 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 29
- ZOHXWSHGANNQGO-DSIKUUPMSA-N 1-amino-4-[[5-[[(2S)-1-[[(1S,2R,3S,5S,6S,16E,18E,20R,21S)-11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.110,14.03,5]hexacosa-10,12,14(26),16,18-pentaen-6-yl]oxy]-1-oxopropan-2-yl]-methylamino]-2-methyl-5-oxopentan-2-yl]disulfanyl]-1-oxobutane-2-sulfonic acid Chemical group CO[C@@H]([C@@]1(O)C[C@H](OC(=O)N1)[C@@H](C)[C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(=O)CCC(C)(C)SSCCC(C(N)=O)S(O)(=O)=O)CC(=O)N1C)\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 ZOHXWSHGANNQGO-DSIKUUPMSA-N 0.000 description 1
- 208000003170 Bronchiolo-Alveolar Adenocarcinoma Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361823317P | 2013-05-14 | 2013-05-14 | |
| US61/823,317 | 2013-05-14 | ||
| US201361828586P | 2013-05-29 | 2013-05-29 | |
| US61/828,586 | 2013-05-29 | ||
| PCT/US2014/037911 WO2014186403A2 (en) | 2013-05-14 | 2014-05-13 | Anti-folr1 immunoconjugate dosing regimens |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018143909A Division JP2018197249A (ja) | 2013-05-14 | 2018-07-31 | 抗ｆｏｌｒ１免疫複合体投与計画 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016520082A JP2016520082A (ja) | 2016-07-11 |
| JP2016520082A5 true JP2016520082A5 (enExample) | 2017-06-29 |
Family
ID=51898993
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016514047A Withdrawn JP2016520082A (ja) | 2013-05-14 | 2014-05-13 | 抗ｆｏｌｒ１免疫複合体投与計画 |
| JP2018143909A Withdrawn JP2018197249A (ja) | 2013-05-14 | 2018-07-31 | 抗ｆｏｌｒ１免疫複合体投与計画 |
| JP2021062774A Withdrawn JP2021102648A (ja) | 2013-05-14 | 2021-04-01 | 抗ｆｏｌｒ１免疫複合体投与計画 |
| JP2023145920A Pending JP2023162436A (ja) | 2013-05-14 | 2023-09-08 | 抗ｆｏｌｒ１免疫複合体投与計画 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018143909A Withdrawn JP2018197249A (ja) | 2013-05-14 | 2018-07-31 | 抗ｆｏｌｒ１免疫複合体投与計画 |
| JP2021062774A Withdrawn JP2021102648A (ja) | 2013-05-14 | 2021-04-01 | 抗ｆｏｌｒ１免疫複合体投与計画 |
| JP2023145920A Pending JP2023162436A (ja) | 2013-05-14 | 2023-09-08 | 抗ｆｏｌｒ１免疫複合体投与計画 |
Country Status (14)
| Country | Link |
|---|---|
| US (5) | US20140363451A1 (enExample) |
| EP (1) | EP2997044A4 (enExample) |
| JP (4) | JP2016520082A (enExample) |
| KR (4) | KR20220054700A (enExample) |
| CN (2) | CN119185571A (enExample) |
| AU (3) | AU2014265587A1 (enExample) |
| BR (1) | BR112015028244A2 (enExample) |
| CA (1) | CA2911499A1 (enExample) |
| HK (1) | HK1222340A1 (enExample) |
| IL (1) | IL268180A (enExample) |
| MX (2) | MX2015015735A (enExample) |
| RU (1) | RU2015149285A (enExample) |
| SG (2) | SG10201701096UA (enExample) |
| WO (1) | WO2014186403A2 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240052894A (ko) | 2010-02-24 | 2024-04-23 | 이뮤노젠 아이엔씨 | 엽산염 수용체 1 항체와 면역접합체 및 이들의 용도 |
| AU2012236219B2 (en) | 2011-04-01 | 2017-02-23 | Immunogen, Inc. | Methods for increasing efficacy of FOLR1 cancer therapy |
| HRP20200482T1 (hr) | 2012-08-31 | 2020-06-26 | Immunogen, Inc. | Dijagnostičke analize i setovi za detekciju folat receptora 1 |
| CA2921975C (en) | 2013-08-30 | 2024-02-13 | Immunogen, Inc. | Antibodies and assays for detection of folate receptor 1 |
| WO2015054400A2 (en) * | 2013-10-08 | 2015-04-16 | Immunogen, Inc. | Anti-folr1 immunoconjugate dosing regimens |
| IL257531B2 (en) * | 2015-09-17 | 2023-04-01 | Immunogen Inc | Medicinal compositions containing anti-folr1 immunoconjugates |
| CN120939250A (zh) | 2016-08-12 | 2025-11-14 | L.E.A.F.控股集团公司 | 聚谷氨酸化抗叶酸剂及其用途 |
| WO2018031967A1 (en) | 2016-08-12 | 2018-02-15 | L.E.A.F. Holdings Group Llc | Polyglutamated antifolates and uses thereof |
| CN111655726B (zh) * | 2017-09-18 | 2024-06-21 | 苏特罗生物制药公司 | 抗叶酸受体α抗体偶联物和其用途 |
| US11730738B2 (en) | 2018-02-07 | 2023-08-22 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated pralatrexate and uses thereof |
| US12220431B2 (en) | 2018-02-07 | 2025-02-11 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated antifolates and uses thereof |
| JP7491573B2 (ja) | 2018-02-07 | 2024-05-28 | エル．イー．エー．エフ． ホールディングス グループ エルエルシー | アルファポリグルタミン酸化メトトレキセートおよびその使用 |
| WO2019157123A1 (en) | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated aminopterin and uses thereof |
| WO2019157133A1 (en) | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated raltitrexed and uses thereof |
| CA3090506A1 (en) | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated tetrahydrofolates and uses thereof |
| CN111954530A (zh) | 2018-02-07 | 2020-11-17 | L.E.A.F.控股集团公司 | γ聚谷氨酸化培美曲塞及其用途 |
| US12246019B2 (en) | 2018-02-07 | 2025-03-11 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated lometrexol and uses thereof |
| EP3749313A4 (en) | 2018-02-07 | 2022-03-16 | L.E.A.F Holdings Group LLC | ALPHA-POLYGLUTAMATE ANTIFOLATES AND ASSOCIATED USES |
| US12239734B2 (en) | 2018-02-07 | 2025-03-04 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated raltitrexed and uses thereof |
| WO2019157138A1 (en) | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated pemetrexed and uses thereof |
| CA3090875A1 (en) | 2018-02-14 | 2019-08-22 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated lometrexol and uses thereof |
| CA3090943A1 (en) | 2018-02-14 | 2019-08-22 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated aminopterin and uses thereof |
| CN111936145A (zh) | 2018-02-14 | 2020-11-13 | L.E.A.F.控股集团公司 | γ聚谷氨酸化氨甲蝶呤及其用途 |
| EP3755335A4 (en) | 2018-02-14 | 2022-06-22 | L.E.A.F Holdings Group LLC | GAMMA POLYGLUTAMIC TETRAHYDROFOLATES AND THEIR USES |
| EP3752156A4 (en) | 2018-02-14 | 2021-10-27 | L.E.A.F Holdings Group LLC | GAMMA-POLYGLUTAMIZED PRALATREXATE AND USES THEREOF |
| EA202092125A1 (ru) | 2018-03-13 | 2020-12-15 | Фейнз Терапьютикс, Инк. | Антитела против рецептора фолата 1 и их применения |
| WO2020092533A2 (en) * | 2018-10-30 | 2020-05-07 | Immunogen, Inc. | Methods of treatment using anti-cd123 immunoconjugates |
| US11396543B2 (en) | 2019-04-29 | 2022-07-26 | Immunogen, Inc. | Biparatopic FR-α antibodies and immunoconjugates |
| CN112794911B (zh) * | 2021-04-14 | 2021-08-03 | 上海偌妥生物科技有限公司 | 人源化抗叶酸受体1抗体及其应用 |
| WO2023116911A1 (zh) * | 2021-12-24 | 2023-06-29 | 百奥泰生物制药股份有限公司 | 抗FRα抗体及其抗体药物偶联物和用途 |
| WO2025036307A1 (zh) * | 2023-08-11 | 2025-02-20 | 百奥泰生物制药股份有限公司 | 抗frα抗体药物偶联物在治疗疾病中的应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020151508A1 (en) * | 2001-02-09 | 2002-10-17 | Schering Corporation | Methods for treating proliferative diseases |
| US20080131366A1 (en) * | 2003-03-17 | 2008-06-05 | Manohar Ratnam | Folate Receptor Gene Modulation For Cancer Diagnosis And Therapy |
| JP4805848B2 (ja) * | 2004-02-12 | 2011-11-02 | モルフォテック、インク． | 腫瘍抗原の生物活性を特異的に阻止するモノクローナル抗体 |
| EP2490715A4 (en) * | 2009-10-21 | 2013-06-26 | Immunogen Inc | NEW DOSAGE ADMINISTRATION REGIMEN AND METHOD OF TREATMENT |
| KR20240052894A (ko) * | 2010-02-24 | 2024-04-23 | 이뮤노젠 아이엔씨 | 엽산염 수용체 1 항체와 면역접합체 및 이들의 용도 |
| AU2012236219B2 (en) * | 2011-04-01 | 2017-02-23 | Immunogen, Inc. | Methods for increasing efficacy of FOLR1 cancer therapy |
| US20120282282A1 (en) * | 2011-04-04 | 2012-11-08 | Immunogen, Inc. | Methods for Decreasing Ocular Toxicity of Antibody Drug Conjugates |
| WO2015054400A2 (en) * | 2013-10-08 | 2015-04-16 | Immunogen, Inc. | Anti-folr1 immunoconjugate dosing regimens |
| IL257531B2 (en) * | 2015-09-17 | 2023-04-01 | Immunogen Inc | Medicinal compositions containing anti-folr1 immunoconjugates |
| US11396543B2 (en) * | 2019-04-29 | 2022-07-26 | Immunogen, Inc. | Biparatopic FR-α antibodies and immunoconjugates |
-
2014
- 2014-05-13 US US14/276,917 patent/US20140363451A1/en not_active Abandoned
- 2014-05-13 SG SG10201701096UA patent/SG10201701096UA/en unknown
- 2014-05-13 RU RU2015149285A patent/RU2015149285A/ru not_active Application Discontinuation
- 2014-05-13 HK HK16110621.8A patent/HK1222340A1/zh unknown
- 2014-05-13 JP JP2016514047A patent/JP2016520082A/ja not_active Withdrawn
- 2014-05-13 KR KR1020227012937A patent/KR20220054700A/ko not_active Ceased
- 2014-05-13 CN CN202410768087.0A patent/CN119185571A/zh active Pending
- 2014-05-13 MX MX2015015735A patent/MX2015015735A/es unknown
- 2014-05-13 SG SG11201509043RA patent/SG11201509043RA/en unknown
- 2014-05-13 KR KR1020247014907A patent/KR20240068778A/ko not_active Ceased
- 2014-05-13 BR BR112015028244A patent/BR112015028244A2/pt not_active Application Discontinuation
- 2014-05-13 EP EP14798020.5A patent/EP2997044A4/en not_active Withdrawn
- 2014-05-13 CN CN201480027385.9A patent/CN105308072A/zh active Pending
- 2014-05-13 KR KR1020157034078A patent/KR20160020421A/ko not_active Ceased
- 2014-05-13 CA CA2911499A patent/CA2911499A1/en active Pending
- 2014-05-13 WO PCT/US2014/037911 patent/WO2014186403A2/en not_active Ceased
- 2014-05-13 KR KR1020237014635A patent/KR20230066648A/ko not_active Ceased
- 2014-05-13 AU AU2014265587A patent/AU2014265587A1/en not_active Abandoned
-
2015
- 2015-11-13 MX MX2019008028A patent/MX2019008028A/es unknown
-
2016
- 2016-12-22 US US15/388,873 patent/US20170239367A1/en not_active Abandoned
-
2018
- 2018-07-31 JP JP2018143909A patent/JP2018197249A/ja not_active Withdrawn
-
2019
- 2019-04-19 US US16/389,396 patent/US20200046634A1/en not_active Abandoned
- 2019-07-21 IL IL268180A patent/IL268180A/en unknown
- 2019-10-15 AU AU2019250121A patent/AU2019250121A1/en not_active Abandoned
-
2021
- 2021-04-01 JP JP2021062774A patent/JP2021102648A/ja not_active Withdrawn
- 2021-10-11 AU AU2021250837A patent/AU2021250837A1/en not_active Abandoned
-
2022
- 2022-04-14 US US17/720,766 patent/US20220378694A1/en not_active Abandoned
-
2023
- 2023-09-08 JP JP2023145920A patent/JP2023162436A/ja active Pending
-
2025
- 2025-03-17 US US19/081,150 patent/US20250262217A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016520082A5 (enExample) | ||
| RU2015149285A (ru) | Схемы дозирования иммуноконъюгата anti-folr1 | |
| TWI596116B (zh) | 包含專一性辨識ｃｄ３８之抗體及硼替佐米（ｂｏｒｔｅｚｏｍｉｂ）之抗腫瘤組合 | |
| JP2020508317A5 (enExample) | ||
| JP2018527383A5 (enExample) | ||
| JP2018070648A5 (enExample) | ||
| RU2018111205A (ru) | Терапевтические комбинации, содержащие анти-folr1 иммуноконъюгаты | |
| JP2021059564A (ja) | 癌治療のための併用療法 | |
| JP2022058802A5 (enExample) | ||
| JP2020534250A5 (enExample) | ||
| JP2016530323A5 (enExample) | ||
| JP2016534039A5 (enExample) | ||
| JP2013520442A5 (enExample) | ||
| JP2017533912A5 (enExample) | ||
| JP2016509582A5 (enExample) | ||
| JP2015532292A5 (enExample) | ||
| JP2014114288A5 (enExample) | ||
| JP2012102122A5 (enExample) | ||
| JP2017535246A5 (enExample) | ||
| HRP20192140T1 (hr) | Režimi doziranja anti-folr1 imunokonjugata | |
| JP2018512402A5 (enExample) | ||
| CN109663130B (zh) | Pd-1抗体和mek抑制剂联合在制备治疗肿瘤的药物中的用途 | |
| JPWO2022270524A5 (enExample) | ||
| CN114340679A (zh) | 用于治疗对pd-1/pd-l1信号传导抑制剂无应答的癌症的方法和药物 | |
| CN109806393B (zh) | 抗pd-1抗体、培美曲塞和铂类药物联合治疗非小细胞肺癌的用途 |